Sexual dimorphism in cardiometabolic and cardiac mitochondrial function in obese rats following sex hormone deprivation

Krekwit Shinlapawittayatorn1,2,3, Wanpitak Pongkan1,4, Sivaporn Sivasinprasasn1,5, Siriporn C. Chattipakorn1,3,6 and Nipon Chattipakorn1,2,3✉

© The Author(s) 2022

OBJECTIVE: Our study aims to test the hypothesis that poorer function of cardiac mitochondria in males, under sex hormone-deprived and obese-insulin-resistant conditions, is responsible for a worse cardiometabolic function than females.

METHODS: One hundred and forty-four rats were subjected to receive either 12 weeks of normal diet (ND) or a high-fat diet (HFD) consumption following the induction of sex hormone deprivation. Temporal evaluations of metabolic parameters, cardiac autonomic modulation, left ventricular (LV) contractile, and mitochondrial functions were measured after starting each feeding protocol for 4, 8, and 12 weeks.

RESULTS: After HFD feeding for 8 weeks, increased plasma insulin and HOMA index were initially observed in male HFD-fed sham-operated rats (M-HFS), male HFD-fed orchiectomized rats (M-HFO), female ND-fed ovariectomized rats (F-OVX), female HFD-fed sham-operated rats (F-HFS), and female HFD-fed ovariectomized rats (F-HFO) groups. In addition, as early as week 4, male ND-fed orchiectomized rats (M-ORX) and M-HFO exhibited impaired cardiac autonomic balance, LV contractile and mitochondrial functions, whereas M-HFS and F-HFO developed these impairments at week 8 and F-OVX and F-HFS exhibited them at week 12.

CONCLUSION: We concluded that sex hormone-deprived females are prone to develop metabolic impairments, whereas males are more likely to have cardiac autonomic impairment, LV contractile and mitochondrial dysfunction even in the absence of obese-insulin-resistant condition. However, under estrogen-deprived condition, these impairments were further accelerated and aggravated by obese-insulin resistance.

INTRODUCTION

Sex differences have been shown to influence the development of many diseases including cardiovascular diseases (CVD) [1–4]. In addition, the prevalence, clinical presentation, severity and outcome for CVD vary based on gender [2]. Although the incidence of CVD is significantly less common in women, the incidence raises after menopause suggesting that this significant sex difference is a key contributor to the CVD benefit [5]. For men, the testosterone level substantially declines [6] and the incidence of several cardiometabolic disorders including metabolic syndrome increases with age [7, 8]. In addition, our previous study demonstrated that orchiectomized (ORX) rats demonstrated impaired left ventricular (LV) contractile function and cardiac autonomic dysregulation [9]. For women, a bilateral ovariectomy (OVX) significantly increased CVD mortality, suggesting the cardioprotective actions of estrogen [10]. Moreover, estrogen deprivation could induce myocardial contractile dysfunction in female rats [11].

In addition to sex hormone deprivation, obesity has been shown to increase the risk for CVD [12]. We previously demonstrated that rats developed obese-insulin resistance [13], cardiac autonomic imbalance, LV contractile dysfunctions, increased production of reactive oxygen species (ROS), and impaired mitochondrial function [14] after feeding with a high-fat diet (HFD) for 8 weeks. Consistently, clinical evidence also demonstrates that after menopause the metabolic syndrome incidence among women increased dramatically [15]. Because sex differences in CVD are prevalent, it is therefore necessary to study the impact of sexual dimorphism on cardiometabolic and cardiac mitochondrial function. Although either sex hormone deprivation or obese-insulin resistance has been shown to affect cardiac function, the link between sexual dimorphism in cardiometabolic parameters, cardiac sympathovagal activity, LV contractile and mitochondrial functions remain poorly understood, especially the temporal effects of combined conditions.

1Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. 2Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. 3Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai 50200, Thailand. 4Department of Veterinary Biosciences and Veterinary Public Health, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. 5School of Medicine, Mae Fah Luang University, Chiang Rai 57100, Thailand. 6Department of Oral Biology and Diagnostic Sciences, Faculty of Dentistry, Chiang Mai University, Chiang Mai 50200, Thailand. ✉email: nchattip@gmail.com

Received: 14 December 2020 Revised: 9 February 2022 Accepted: 24 February 2022
Published online: 17 March 2022
We hypothesized that under both sex hormone-deprived and obese-insulin-resistant conditions, males have a poorer cardiometabolic function and worse cardiac mitochondrial function than females. Understanding sex-related differences in the phenotypic expression of cardiometabolic and cardiac mitochondrial function is important because it is possible that different therapies and treatments could be targeted for men and women, especially in the presence of combined conditions.

MATERIAL AND METHODS

Animals

The experimental studies were conducted in accordance with the NIH guidelines for the use of laboratory animals and were approved by the Animal Care and Use Committee (Chiang Mai University). Both male and female 5–6 weeks old Wistar rats were provided by the National Laboratory Animal Center (Mahidol University, Bangkok, Thailand). Under the temperature of 22–25 °C, rats were housed one rat per cage with a light-dark (12h:12h) cycle. Rats were fed (ad libitum) with either a normal diet (ND) (Mouse Feed Food No. 082, C.P. Company, Thailand) or an HFD.

Orchietomy and ovarietomy procedures

Isoflurane (2–3%) was used as an anesthetic agent. Male rats were subjected to orchietomy (ORX) as described previously [16]. Female rats were subjected to the bilateral ovarietomy (OVX) procedure as previously described [17]. Then, rats were subcutaneously injected with analgesic drugs and antibiotics for 3 days. Then, a clear box with dry bedding was used to house rats individually. Rats in the ND group were fed with standard laboratory chow (19.77% E from fat). In contrast, rats in the HFD group were fed with an HFD (59.28% E from fat). The ingredients of HFD are as follows: standard rat diet, cholesterol, casein, DL-methionine, lard, NaCl, vitamins, and yeast powder [13].

Experimental design

One hundred and forty-four rats were randomly subjected to a sham-operated group and ORX or OVX group. Rats were returned to the cage for recovery for 1 week after the operation. Then, rats in each group (n = 6/group for each duration in each dietary group) were subjected to receive different dietary consumption (ND or HFD) for 4, 8, and 12 weeks. Thus, there are eight experimental groups as follow: (1) male ND-fed sham-operated rats (M-NDS), (2) male ND-fed orchietomized rats (M-ORX), (3) male HFD-fed sham-operated rats (M-HFS), (4) male HFD-fed orchietomized rats (M-HFO), (5) female ND-fed sham-operated rats (F-NDS), (6) female ND-fed orchietomized rats (F-ORX), (7) female HFD-fed sham-operated rats (F-HFS), and (8) female HFD-fed orchietomized rats (F-HFO).

Both body weight and food consumption were daily noted, and blood specimens were collected at 4th, 8th, and 12th weeks after 5 weeks of sex hormone deprivation. For the assessment of metabolic parameters, insulin resistance, sex hormone, and plasma and cardiac malondialdehyde levels, metabolic parameters were measured by an enzymatic colorimetric assay using a commercially available kit (Biotech, Bangkok, Thailand). Fasting plasma HDL, LDL, and insulin levels were measured using a sensitive, colorimetric and fluorometric assay (BioVision, Friedewald’s equation [24] and Sandwich ELISA (Millipore), respectively.

Insulin resistance was determined using the homeostasis model assessment (HOMA) [25]. A higher HOMA index indicates a greater degree of insulin resistance [13]. Total plasma testosterone and estradiol levels were determined by ELISA and a competitive enzyme immunoassay kit (Cayman Chemical Company, MI, USA), respectively.

Plasma and cardiac malondialdehyde (MDA) levels were determined using an HPLC system (ThermoScientific) [18]. The concentrations of either plasma or cardiac thiobarbituric acid reactive substances (TBARS) were obtained from a standard curve, and reported as an MDA equivalent concentration [26].

Determination of metabolic parameters, insulin resistance, sex hormone, and plasma and cardiac malondialdehyde levels

Determination of HRV

The cardiac autonomic balance was accessed by determining heart rate variability (HRV) [19]. An ECG was performed at 4th, 8th, and 12th weeks in each rat after being fed with an ND or HFD. The ECG was continuously recorded for 20 min using PowerLab (PowerLab 4/25T, AD Instruments, Australia) with chart 5.0, while the animals were still conscious. MATLAB program was used to analyze the ECG data [20]. The analysis of HRV was presented in the frequency domain as follows: A high frequency (HF, 0.60–0.3 Hz) and a low frequency (LF, 0.20–0.6 Hz), which indicates vagal and sympathovagal activities, respectively [19]. The balance of cardiac sympathovagal activity was evaluated by using the LF/HF ratio [21]. The autonomic shift toward sympathovagal activity was identified by an increase in LF/HF ratio [14].

Determination of cardiac function

Rats were anesthetized by isoflurane inhalation (2% isoflurane, 98% O2). Then, rats were restrained by fixing the four limbs to a small animal surgery board using a fixing tape. An echocardiograph (SONOS5400, Philips) was used to determine LV function. The LV function was analyzed at baseline and after feeding protocol. The LV ejection fraction (EF) was measured by using standard M-mode echocardiography.

Surrogate measures of cardiac mitochondrial function

Both 50 mg/kg of zotell and 3 mg/kg of xylazine were used as an anesthetic. The isolated cardiac mitochondria were collected and the protein concentration was measured as described previously [22]. After the application of 2 mM of H2O2, 2 μM of dichlorohydrofluorescein diacetate dye was used to determine the percent change in cardiac mitochondrial ROS production [22]. A fluorescent microplate reader (BioTek Instruments, Winoski, USA) was used to determine the ROS level at the excitation wavelength (λex) and the emission wavelength (λem) at 485 nm (bandwidth 5 nm) and 530 nm (bandwidth 10 nm), respectively. Increased cardiac mitochondrial ROS generation is indicated by increased fluorescent intensity [23].

After application of 2 mM of H2O2, the percent change of cardiac mitochondria membrane potential were determined by staining with 5 μM of mitochondrial probe 5′,6′-tetrachloro-1,1′,3′,3′-tetrathiacylenizimidato-zolcarbocyanine iodide (JC-1) [22] and determined by a microplate reader for fluorescent detection. The depolarization of the mitochondria of cardiac mitochondria was identified as a decreased red/green fluorescent ratio [23].

The level of mitochondrial swelling was determined from a suspension of isolated cardiac mitochondria using a microplate reader (Synergy HT, BioTek). Mitochondria (0.4 mg/mL) were incubated in respiration buffer as previously described [22]. The swelling of cardiac mitochondria was determined by a decrease in the absorbance by the mitochondrial suspension at 540 nm [23].

Determination of metabolic parameters, insulin resistance, sex hormone, and plasma and cardiac malondialdehyde levels

Metabolic parameters were measured by an enzymatic colorimetric assay using a commercially available kit (Biotech, Bangkok, Thailand). Fasting plasma HDL, LDL, and insulin levels were measured using a sensitive, colorimetric and fluorometric assay (BioVision), Friedewald’s equation [24] and Sandwich ELISA (Millipore), respectively.

Plasma and cardiac malondialdehyde (MDA) levels were determined using an HPLC system (ThermoScientific) [18]. The concentrations of either plasma or cardiac thiobarbituric acid reactive substances (TBARS) were obtained from a standard curve, and reported as an MDA equivalent concentration [26].

Statistical analysis

All values were presented as mean ± SEM. For cardiac function, LF/HF ratio and the surrogate measures of mitochondrial function. SPSS program (SPSS version 23, SPSS Inc.) was used to determine the significance of the difference between the mean by using a three-way-ANOVA for each time period (4, 8, and 12 weeks) with gender, hormone, and diet as the three factors, and was followed by pairwise Tukey’s tests. The difference between the mean of the blood serum testosterone and estradiol levels were determined using the unpaired Student’s t-test. The difference between the groups for the rest of the parameters was analyzed by two-way ANOVA, followed by LSD post-hoc analysis. P < 0.05 was used as a criterion of statistical significance.

RESULTS

Sex-related differences in the development of insulin resistance in the presence of sex hormone deprivation. At week 4, sex hormone deprivation was confirmed by decreased plasma testosterone (Table 1) or estradiol (Table 2) levels. Orchietomized or ovarietomized rats in both dietary groups (M-ORX, M-HFO, F-OVX, and F-HFO) had significantly decreased plasma testosterone or estradiol levels, when compared with sex-matched NDS at the same time points. The body weight of M-HFS and F-HFS were significantly increased compared with
sex-matched NDS. In contrast, the body weight, food intake, and visceral fat of M-ORX, but not F-OVX, were decreased when compared with M-NDS. However, the metabolic parameters were not different between M-ORX, M-HFS, M-HFO, F-OVX, F-HFS, and F-HFO compared with sex-matched NDS (Tables 3–5).

At week 8, the body weight, food consumption, and visceral fat mass of M-ORX were not different compared with the results at week 4. In contrast, F-OVX had significantly increased body weight compared with F-NDS. Although M-ORX did not develop peripheral insulin resistance, peripheral insulin resistance was detected in F-OVX and the HFD groups (M-HFS, M-HFO, F-HFS, and F-HFO), as demonstrated by increased levels of insulin and HOMA index (Tables 3–5).

At week 12, the body weight and food consumption of M-ORX and F-OVX were similar to the results at week 8. However, the visceral fat of F-OVX was significantly increased compared with the age-matched F-NDS. M-ORX did not develop peripheral insulin resistance at week 12. In contrast, F-OVX- and HFD-treated rats (M-HFS, M-HFO, F-HFS, and F-HFO) still demonstrated consistent impairments in metabolic parameters compared with sex-matched NDS rats (Tables 3–5). In addition, the body weight of M-HFS was markedly increased compared with M-NDS, whereas the body weight and visceral fat mass were not changed or even decreased in the orchietomized rats (M-ORX and M-HFO) compared with the age-matched M-NDS (Tables 3–5).

**Sex-related differences in the development of oxidative stress in the presence of sex hormone deprivation**

At week 4, both serum and cardiac MDA were significantly increased in M-ORX and M-HFO groups compared with the age-matched NDS (Tables 3 and 5). Moreover, at week 8, both serum and cardiac MDA were significantly increased in M-ORX, M-HFS, M-HFO, and F-HFO groups compared with the age-matched NDS (Tables 3–5). At week 12, both serum and cardiac MDA were markedly increased in M-ORX, M-HFS, M-HFO, F-OVX, F-HFS, and F-HFO compared with the age-matched NDS (Tables 3–5).

**Sex-related differences in the development of cardiac dysfunction and HRV impairment in the presence of sex hormone deprivation**

For the LV contractile function of male rats, a marked decrease of %EF at week 4 was detected and continued to decrease by weeks 8 and 12 in both M-ORX and M-HFO groups, when compared with age-matched NDS (Fig. 1A–C). Unlike M-ORX and M-HFO groups, when compared with age-matched M-NDS, M-HFS demonstrated a marked reduction in %EF later at weeks 8 and 12 of the study (Fig. 1B, C).

For the LV function of female rats, the %EF was not significantly different between F-OVX and age-matched F-NDS at weeks 4 and 8 (Fig. 1A, B). However, beginning at week 8, F-HFO group exhibited a significant reduction in %EF (Fig. 1B). In addition, reduced %EF in F-OVX and F-HFS groups was not detected until week 12 (Fig. 1C). In addition, there was no statistically significant three-way interaction between gender, food, and hormone at week 4 on the LV function, F(1, 16) = 4.268, P = 0.06. However, there was a statistically significant three-way interaction between gender, food, and hormone at week 8 (F(1, 16) = 18.626, P = 0.001) and week 12 (F(1, 16) = 18.445, P = 0.001).

Consistent with the %EF profiles, an impaired cardiac autonomic balance was first detected in both M-ORX and M-HFO groups (Fig. 2A). Moreover, the ratio of LF/HR in both M-ORX and M-HFO groups markedly increased from week 4 onward when compared with the age-matched M-NDS group. Furthermore, by weeks 8 and 12, the M-HFS group exhibited cardiac autonomic dysregulation (Fig. 2A, B).

In female rats, at week 4, the cardiac autonomic regulation did not differ among groups (Fig. 2A). However, at week 8, depressed HRV was detected only in F-HFO group (Fig. 2B), suggesting that the impaired cardiac autonomic regulation was firstly developed in the F-HFO group. Moreover, when compared with the age-matched F-NDS group, increased LF/HR ratio in F-OVX, F-HFS and F-HFO groups were detected at week 12 (Fig. 2). Interestingly, a further increase in LF/HR ratio in F-HFO rats was detected at week 12 (Fig. 2C). However, a statistically significant three-way interaction between gender, food, and hormone was detected only at week 8 on the LF/HR ratio, F(1, 16) = 6.129, P = 0.025.

### Table 1. Summary of blood serum testosterone levels.

| Experimental groups | Week | 4         | 8         | 12        |
|---------------------|------|-----------|-----------|-----------|
| Blood serum testosterone (ng/dL) | M-NDS | 1.37 ± 0.68 | 1.61 ± 0.83 | 1.10 ± 0.16 |
|                     | M-ORX | 0.07 ± 0.12*† | 0.04 ± 0.01*† | 0.06 ± 0.01*† |
|                     | M-HFS | 0.99 ± 0.41*† | 1.05 ± 0.27* | 0.50 ± 0.06*† |
|                     | M-HFO | 0.11 ± 0.01*† | 0.11 ± 0.01*† | 0.08 ± 0.01*† |

M-NDS male normal diet sham, M-ORX male orchiectomy, M-HFS male high-fat diet sham, M-HFO male high-fat diet with orchiectomy.

*P < 0.05 vs. age-matched M-NDS, †P < 0.05 vs. age-matched M-HFS, ‡P < 0.05 vs. age-matched M-ORX.

### Table 2. Summary of blood serum estradiol levels.

| Experimental groups | Week | 4         | 8         | 12        |
|---------------------|------|-----------|-----------|-----------|
| Blood serum estradiol (ng/dL) | F-NDS | 13.9 ± 3.48 | 11.3 ± 1.43 | 13.1 ± 1.72 |
|                     | F-OVX | 4.33 ± 1.06*† | 5.16 ± 0.31*† | 6.39 ± 0.79*† |
|                     | F-HFS | 13.76 ± 2.03* | 10.26 ± 0.83* | 13.5 ± 1.19* |
|                     | F-HFO | 3.06 ± 0.24* | 5.67 ± 0.49* | 6.25 ± 0.46* |

F-NDS female normal diet sham, F-OVX female ovariectomy, F-HFS female high-fat diet sham, F-HFO female high-fat diet with ovariectomy.

*P < 0.05 vs. age-matched F-NDS, †P < 0.05 vs. age-matched F-HFS, ‡P < 0.05 vs. age-matched F-OVX.
Table 3. Effects of sex hormone on metabolic parameters in normal diet-fed male and female rats.

| Metabolic parameters       | 4 weeks of dietary consumption | 8 weeks of dietary consumption | 12 weeks of dietary consumption |
|----------------------------|--------------------------------|--------------------------------|--------------------------------|
|                            | Male                          | Female                         | Male                          | Female                         | Male                          | Female                         | Male                          | Female                         |
|                            | M-NDS                         | M-ORX                          | F-NDS                         | F-OVX                          | M-NDS                         | M-ORX                          | F-NDS                         | F-OVX                          |
| Body weight (g)            | 444 ± 14.3                    | 420 ± 9.0*                     | 270 ± 10.5                    | 281 ± 6.0                      | 452 ± 8.6                     | 443 ± 6.6*                     | 305 ± 5.9*                    | 304 ± 5.9*                     |
| Food intake (g/day)        | 23 ± 0.6                      | 18 ± 0.4*                      | 16 ± 0.5                      | 16 ± 0.7*                      | 22 ± 0.5                      | 16 ± 0.7*                      | 15 ± 1.3                      | 14 ± 1.1                       |
| Visceral fats (g)          | 24 ± 1.5                      | 17 ± 2.2*                      | 12 ± 1.0                      | 10 ± 1.0                       | 30 ± 1.0                      | 16 ± 0.6*                      | 10 ± 0.5                      | 10 ± 1.0                       |
| Plasma glucose (mg/dL)     | 126 ± 3.1                     | 128 ± 8.2                      | 123 ± 10.9                    | 124 ± 10.9                     | 125 ± 7.9                     | 127 ± 6.0                      | 127 ± 6.0                     | 136 ± 3.8                      |
| Plasma insulin (ng/mL)     | 2.1 ± 0.4                     | 2.0 ± 0.3                      | 0.8 ± 0.1                     | 0.9 ± 0.1                      | 1.9 ± 0.2                     | 1.9 ± 0.1                      | 1.1 ± 0.1                     | 1.6 ± 0.2*                     |
| HOMA index                 | 12.1 ± 2.1                    | 10.7 ± 1.2                     | 5.7 ± 0.4                     | 6.1 ± 0.8                       | 9.0 ± 1.4                     | 11.6 ± 0.9                     | 5.9 ± 1.0                     | 13.4 ± 1.4                     |
| Cholesterol (mg/dL)        | 89 ± 3.5                      | 91 ± 5.0                       | 99 ± 6.7                      | 98 ± 8.5                       | 91 ± 4.1                      | 93 ± 4.3                       | 109 ± 6.1                     | 106 ± 2.8                      |
| HDL (mg/dL)                | 30 ± 1.0                      | 32 ± 1.6                       | 31 ± 1.3                      | 33 ± 1.9                       | 34 ± 1.8                      | 33 ± 3.0                       | 31 ± 1.9                      | 34 ± 0.6                       |
| LDL (mg/dL)                | 60 ± 2.6                      | 65 ± 1.5                       | 76 ± 5.3                      | 78 ± 6.7                       | 58 ± 4.5                      | 68 ± 6.6                       | 78 ± 5.1                      | 89 ± 3.4                       |
| Triglyceride (mg/dL)       | 135 ± 1.2                     | 139 ± 8.1                      | 35 ± 1.3                      | 30 ± 2.4                       | 129 ± 7.7                     | 130 ± 8.4                      | 45 ± 4.0                      | 41 ± 3.0                       |
| Serum MDA (µmol/mL)        | 4.6 ± 0.03                    | 5.3 ± 0.12*                    | 3.6 ± 0.37                    | 5.0 ± 0.07                     | 5.0 ± 0.07                    | 5.8 ± 0.14*                    | 3.5 ± 0.31                    | 4.2 ± 0.4                      |
| Cardiac MDA (µmol/mL)      | 1.5 ± 0.26                    | 3.1 ± 0.76*                    | 2.4 ± 0.43                    | 2.6 ± 0.61                     | 2.0 ± 0.22                    | 4.7 ± 1.01*                    | 2.6 ± 0.39                    | 2.5 ± 0.20                     |

HDL: high-density lipoprotein, HOMA: homeostatic model assessment, LDL: low-density lipoprotein, M-NDS: male normal diet sham, M-ORX: male orchiectomy, F-NDS: female normal diet sham, F-OVX: female ovariectomy.

*P < 0.05 vs. age-matched NDS in the same gender.

Table 4. Effects of dietary consumption on metabolic parameters in male and female rats.

| Metabolic parameters       | 4 weeks of dietary consumption | 8 weeks of dietary consumption | 12 weeks of dietary consumption |
|----------------------------|--------------------------------|--------------------------------|--------------------------------|
|                            | Male                          | Female                         | Male                          | Female                         | Male                          | Female                         |
|                            | M-NDS                         | M-HFS                          | F-NDS                         | F-HFS                          | M-NDS                         | M-HFS                          | F-NDS                         | F-HFS                          |
| Body weight (g)            | 444 ± 14.3                    | 482 ± 12.4*                    | 270 ± 10.5                    | 281 ± 6.0                      | 452 ± 8.6                     | 526 ± 14.7*                    | 305 ± 5.9*                    | 344 ± 8.7*                     |
| Food intake (g/day)        | 23 ± 0.6                      | 24 ± 0.1                       | 16 ± 0.5                      | 17 ± 0.4                       | 22 ± 0.5                      | 23 ± 0.1                       | 15 ± 1.3                      | 16 ± 0.6                       |
| Visceral fats (g)          | 24 ± 1.5                      | 35 ± 2.2*                      | 12 ± 1.0                      | 20 ± 1.6*                      | 30 ± 1.0                      | 51 ± 2.5*                      | 10 ± 0.5                      | 25 ± 1.6*                      |
| Plasma glucose (mg/dL)     | 126 ± 3.1                     | 130 ± 8.2                      | 123 ± 10.9                    | 125 ± 7.9                      | 127 ± 5.2                     | 134 ± 8.3                      | 136 ± 3.8                     | 133 ± 4.4                      |
| Plasma insulin (ng/mL)     | 2.1 ± 0.4                     | 2.1 ± 0.2                      | 0.8 ± 0.1                     | 0.9 ± 0.1                      | 1.9 ± 0.2                     | 2.9 ± 0.1*                     | 1.1 ± 0.1                     | 1.5 ± 0.2*                     |
| HOMA index                 | 12.1 ± 2.1                    | 11.2 ± 0.9                     | 5.7 ± 0.4                     | 6.5 ± 1.7                      | 10.7 ± 1.4                    | 16.6 ± 1.0*                    | 5.9 ± 1.0                     | 13.9 ± 3.4*                    |
| Cholesterol (mg/dL)        | 89 ± 3.5                      | 96 ± 4.1                       | 99 ± 6.7                      | 99 ± 10.6                      | 91 ± 4.1                      | 104 ± 5.5*                     | 109 ± 6.1                     | 101 ± 3.5                      |
| HDL (mg/dL)                | 30 ± 1.0                      | 29 ± 1.7                       | 31 ± 1.3                      | 28 ± 2.1                       | 34 ± 1.8                      | 27 ± 1.6*                      | 31 ± 1.9                      | 29 ± 1.8                       |
| LDL (mg/dL)                | 60 ± 2.6                      | 67 ± 5.3                       | 76 ± 5.3                      | 74 ± 6.8                       | 58 ± 4.5                      | 77 ± 8.1*                      | 78 ± 5.1                      | 83 ± 4.6                       |
| Triglyceride (mg/dL)       | 135 ± 12.1                    | 138 ± 15.6                     | 35 ± 3.4                      | 36 ± 4.0                       | 129 ± 7.7                     | 116 ± 17.7                     | 45 ± 4.0                      | 46 ± 1.4                       |
| Serum MDA (µmol/mL)        | 4.6 ± 0.03                    | 5.0 ± 0.1                      | 3.5 ± 0.42                    | 3.5 ± 0.09                     | 5.0 ± 0.07                    | 5.8 ± 0.14*                    | 3.5 ± 0.31                    | 3.7 ± 0.48                     |
| Cardiac MDA (µmol/mL)      | 1.5 ± 0.26                    | 1.5 ± 0.15                     | 2.4 ± 0.43                    | 2.3 ± 0.04                     | 2.0 ± 0.22                    | 4.4 ± 0.05*                    | 2.6 ± 0.39                    | 2.8 ± 0.81                     |

HDL: high-density lipoprotein, HOMA: homeostatic model assessment, LDL: low-density lipoprotein, M-NDS: male normal diet sham, M-HFS: male high-fat diet sham, F-NDS: female normal diet sham, F-HFS: female high-fat diet sham.

*P < 0.05 vs. age-matched NDS in the same gender.
Sex-related differences in the development of cardiac mitochondrial impairment in the presence of sex hormone deprivation

In male rats under sex hormone deprivation (M-ORX and M-HFO), an impaired cardiac mitochondrial function was observed early at week 4 and continued to weeks 8 and 12, as demonstrated by increased production of mitochondrial ROS level (Fig. 3), mitochondrial depolarization (Fig. 4), and mitochondrial swelling (Fig. 5) when compared with age-matched M-NDS. In M-HFS group, the cardiac mitochondrial dysfunction was detected at week 8 (Figs. 3B, 4B, and 5B).

In female rats, the surrogate of cardiac mitochondrial function did not differ among groups at week 4 (Figs. 3A, 4A, and 5A). At week 8, an impaired cardiac mitochondrial function was found only in F-HFO group (Figs. 3B, 4B, and 5B). Interestingly, both F-OVX and F-HFS rats exhibited cardiac mitochondrial dysfunction at week 12 (Figs. 3C, 4C, and 5C).

In addition, for the cardiac mitochondrial ROS production, we found that there was no statistically significant three-way interaction between gender, food and hormone at week 4, $F(1, 16) = 2.027$, $P = 0.174$. However, there was a statistically significant three-way interaction between gender, food and hormone at week 8 ($F(1, 16) = 7.742$, $P = 0.013$) and week 12 ($F(1, 16) = 12.981$, $P = 0.002$). Interestingly, there was no statistically significant three-way interaction between gender, food and hormone at all time points on the alteration of cardiac mitochondrial membrane potential. For the cardiac mitochondrial swelling, there was a statistically significant three-way interaction between gender, food and hormone only at week 8, $F(1, 16) = 10.957$, $P = 0.004$.

**DISCUSSION**

The present study demonstrated that following sex hormone deprivation, there is an obvious sex-associated impact on cardiac contractile and mitochondrial functions in obese-insulin-resistant condition. Moreover, estrogen deprivation alone can cause peripheral insulin resistance in female rats, whereas peripheral insulin resistance did not observe in testosterone deprivation condition in male rats. Secondly, under sex hormone-deprived condition, females are generally more susceptible to develop metabolic disorders, whereas males are more susceptible to develop LV and cardiac mitochondrial impairments even in the absence of obese-insulin-resistant condition. Thirdly, in females, obese-insulin resistance further accelerated and aggravated these impairments under the estrogen-deprived condition. Thus, our study clearly demonstrated the sex-associated impact on cardiac contractile and mitochondrial function in obese-insulin-resistant females following estrogen withdrawal. These findings are summarized in Table 6.

Under the deprivation of sex hormone condition, females are more prone to develop metabolic impairments than males

We found that estrogen deprivation could induce metabolic parameters impairment as early as week 8. In contrast, testosterone deprivation alone did not impair metabolic parameters, except for weight loss, at all measured time points, suggesting that females are more susceptible to develop metabolic disorders than males under sex hormone deprivation condition. Previous studies reported that girls are more insulin resistant than boys in puberty and adolescence [27, 28]. Furthermore, both Mauritius study [29] and in the RIAD cohort [30] have shown that women had more pronounced impaired glucose tolerance and lower fasting glucose levels than men. In addition, in an elderly population, the Rancho Bernardo Study has demonstrated that hyperglycemia was more frequent in women than in men [31]. The more susceptibility to develop insulin resistance in females might be explained by the more favorable fat distribution in women [32]. In our study, F-OVX, but not M-ORX, had significantly

**Table 5. Effects of dietary consumption combined with sex hormone deprivation on metabolic parameters in male and female rats.**

| Metabolic parameters | 4 weeks of dietary consumption | 8 weeks of dietary consumption | 12 weeks of dietary consumption |
|----------------------|--------------------------------|--------------------------------|---------------------------------|
|                      | Male                           | Female                         | Male                            | Female                         | Male                            | Female                         | Male                            | Female                         |
| Body weight (g)      | 444 ± 14.3                    | 458 ± 12.0                     | 270 ± 10.5                      | 327 ± 4.4*                     | 452 ± 6.6                      | 498 ± 11.6*                    | 278 ± 5.8                      | 388 ± 8.5*                     |
| Food intake (g/day)  | 23 ± 0.6                       | 23 ± 0.3                       | 16 ± 0.5                        | 18 ± 0.3                       | 22 ± 0.5                       | 21 ± 0.4                       | 15 ± 1.3                       | 17 ± 0.5                       |
| Visceral fats (g)    | 24 ± 1.5                       | 29 ± 0.6*                      | 12 ± 1.0                        | 22 ± 2.2*                      | 30 ± 1.0                       | 37 ± 2.3*                      | 10.5 ± 1.1                     | 30 ± 2.2*                      |
| HDL (mg/dL)         | 30 ± 1.0                       | 28 ± 2.2*                      | 31 ± 1.3                        | 29 ± 1.3                       | 34 ± 1.8                       | 27 ± 3.2*                      | 31 ± 1.9                       | 30 ± 1.8                       |
| LDL (mg/dL)         | 60 ± 2.6                       | 65 ± 8.9                       | 76 ± 5.3                        | 80 ± 8.3                       | 58 ± 4.5                       | 90 ± 6.7*                      | 78 ± 5.1                       | 119 ± 3.1*                     |
| Triglyceride (mg/dL)| 135 ± 12.1                     | 140 ± 8.9                      | 35 ± 3.4                        | 32 ± 4.2                       | 129 ± 7.7                      | 132 ± 2.4                      | 45 ± 4.0                       | 46 ± 4.4                       |

High-density lipoprotein, HDL; homeostatic model assessment, HOMA; low-density lipoprotein, LDL; mitochondrial membrane potential, M-MP; mitochondrial depolarization, M-DP; mitochondrial swelling, M-SW; hyperglycemia, HYG; fasting glucose level, F-GL; obesity, OB; insulin resistance, IR; male normal diet sham, M-NDS; male high-fat diet with orchiectomy, M-HFO; female normal diet sham, F-NDS; female high-fat diet with ovariectomy, F-HFO.

* $P < 0.05$ vs. age-matched NDS in the same gender.
Fig. 1  The effect of sex hormone and dietary consumption on LV function at different time courses (4, 8, and 12 weeks). A The LV function at 4 weeks. B The LV function at 8 weeks. C The LV function at 12 weeks. *P < 0.05 vs sex-matched ND-Sham (n = 6/group). †P < 0.05 vs male orchiectomized rats (n = 6/group). ‡P < 0.05 vs female high-fat diet-fed ovariectomized rats (n = 6/group). S sham, ND normal diet, HFD high-fat diet, ORX orchiectomized rats, OVX ovariectomized rats.

Fig. 2  The effect of sex hormone and dietary consumption on LF/HF ratio at different time courses (4, 8, and 12 weeks). A The LF/HF ratio at 4 weeks. B The LF/HF ratio at 8 weeks. C The LF/HF ratio at 12 weeks. *P < 0.05 vs sex-matched ND-Sham (n = 6/group). †P < 0.05 vs male orchiectomized rats (n = 6/group). ‡P < 0.05 vs female high-fat diet-fed ovariectomized rats (n = 6/group). S sham, ND normal diet, HFD high-fat diet, ORX orchiectomized rats, OVX ovariectomized rats.

Fig. 3  The effect of sex hormone and dietary consumption on cardiac mitochondrial ROS level at different time courses (4, 8, and 12 weeks). A The cardiac mitochondrial ROS level at 4 weeks. B The cardiac mitochondrial ROS level at 8 weeks. C The cardiac mitochondrial ROS level at 12 weeks. *P < 0.05 vs sex-matched ND-Sham (n = 6/group). †P < 0.05 vs male orchiectomized rats (n = 6/group). ‡P < 0.05 vs female high-fat diet-fed ovariectomized rats (n = 6/group). S sham, ND normal diet, HFD high-fat diet, ORX orchiectomized rats, OVX ovariectomized rats.
increased body weight and visceral fat compared with F-NDS. A previous study has shown that increased adipocyte deposition in obesity caused an increased adipocytokine and decreased adiponectin levels [33]. Moreover, adiponectin levels are significantly reduced in obese subjects [34] and patients with type 2 diabetes [35]. Thus, it is reasonable to speculate that increased adipocytokine and decreased adiponectin levels after estrogen deprivation might be an underlying cause of peripheral insulin resistance in females.

Males are more susceptible to develop LV and cardiac autonomic imbalance than females even in the absence of obese-insulin-resistant condition

Although testosterone deprivation in M-ORX rats did not alter metabolic parameters, it impaired LV contractile function and cardiac autonomic control as early as week 4. In contrast, LV contractile dysfunction and cardiac autonomic imbalance in F-OVX rats was not detected until week 12, suggesting the gender-specific pathological differences in the cardiometabolic disorders. Moreover, testosterone deprivation accelerated the impairment of LV contractile function and cardiac autonomic balance in M-HFO rats. Consistently, we previously reported that testosterone deprivation accelerates, but not aggravates, the impairment of LV function and cardiac autonomic regulation in obese-orchiectomized male rats [16]. Interestingly, although either F-OVX or F-HFS alone could impair LV contractile function and cardiac autonomic regulation, the acceleration of this impairment was shown in F-HFO rats. This finding was consistent with our previous study that obesity and insulin resistance both accelerate and aggravate the impairment of cardiac contractile function and cardiac sympathovagal balance under estrogen deprivation [36].

There are clear sex differences in the temporal alteration of cardiometabolic and cardiac autonomic functions

In the present study, we have shown that sex hormone deprivation, obese-insulin resistance or combined condition could impair cardiac contractile function and cardiac sympathovagal balance in both genders. However, there is a clear sexual dimorphism in the temporal alteration of cardiometabolic and cardiac autonomic functions. Although testosterone deprivation did not alter metabolic parameters, it significantly reduced LV contractile function and impaired cardiac autonomic balance as observed as early as week 4.
In contrast, there was earlier development of cardiac autonomic imbalance in the F-HFO rats at week 8 suggesting that in estrogen-deprived condition obese-insulin resistance accelerated the development of cardiac autonomic imbalance. We previously demonstrated that cardiac autonomic imbalance was associated with increased sympathetic tone and ROS production [37]. Moreover, increased MDA and ROS levels could impair cardiac autonomic balance via ROS-induced cardiac sympathetic overactivity [38].

Mitochondria are known as the cellular energy factories, and they also participate in many other functions including ROS production. In addition, cardiac mitochondria are crucial to maintain proper cardiac contractile function [39]. Interestingly, a strong tissue and sex specificity was detected in mitochondria. In female cardiomyocytes, mitochondria produce less ROS and have a higher capacity of antioxidant defenses than the male ones [40–42]. Moreover, female cardiac mitochondria have a greater mitochondrial calcium retention capacity compared with males [43]. Therefore, sexual dimorphism of cardiac mitochondria may contribute to differences in the temporal development of cardiometabolic and cardiac autonomic impairments as shown in the present study. Our study limitation was that we did not directly measure the oxidative function of cardiac mitochondria. However, increased production of cardiac mitochondrial ROS level, membrane depolarization and swelling have a direct correlation with oxidative stress-induced mitochondrial dysfunction. Thus, future studies are required to elucidate the impacts of sexual dimorphism on cardiac mitochondrial respiratory function and aerobic capacity under these conditions.

**CONCLUSIONS**

This study demonstrated that following sex hormone deprivation there is an obvious sex-associated impact on cardiac contractile and mitochondrial functions in the presence of obese-insulin resistance. Specifically, under sex hormone-deprived condition, females are generally more susceptible to develop metabolic disorders, whereas males are more susceptible to develop cardiac autonomic, LV and mitochondrial dysfunction even in the absence of obesity and insulin-resistant condition. However, in the presence of estrogen deprivation condition, the severity of these impairments was further accelerated and aggravated in obese-insulin-resistant females. Our findings suggest that different therapeutic strategies could be targeted for men and women due to sexual dimorphism.

**REFERENCES**

1. Arain FA, Kuniyoshi FH, Abdalrhim AD, Miller VM. Sex/gender medicine. The biological basis for personalized care in cardiovascular disease. Circ J. 2009;73:1774–82.
2. Group EUCCS, Regitz-Zagrosek V, Oertelt-Prigione S, Prescott E, Franconi F, Gerdt E. Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. Eur Heart J. 2016;37:24–34.
3. Ober C, Loisel DA, Gilad Y. Sex-specific genetic architecture of human disease. Nat Rev Genet. 2008;9:911–22.
4. Popkov VA, Plotnikov EY, Silachev DN, Zorova LD, Pevzner IB, Jankauskas SS, et al. Diseases and aging: gender matters. Biochem (Mosc). 2015;80:1560–70.
5. Vitale C, Mendelsohn ME, Rosano GM. Gender differences in the cardiovascular effect of sex hormones. Nat Rev Cardiol. 2009;6:532–42.
6. Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, Williams RE, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2009;94:4241–7.
7. Grossmann M, Thomas MC, Panagiotopoulos S, Sharpe K, Macisaac RJ, Clarke S, et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab. 2008;93:1834–40.
8. Oskui PM, French WJ, Herring MJ, Mayeda GS, Burstein S, Klener RA. Testosterone and the cardiovascular system: a comprehensive review of the clinical literature. J Am Heart Assoc. 2013;2:e000272.
9. Pongkan W, Chattipakorn SC, Chattipakorn N. Chronic testosterone replacement exerts cardioprotection against cardiac ischemia-reperfusion injury by attenuating mitochondrial dysfunction in testosterone-deprived rats. PLoS One. 2015;10:e0122503.
10. Rivera CM, Grossardt BR, Rhodes DJ, Brown RD Jr, Roger VL, Melton LJ III, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause. 2009;16:15–23.

11. Ribeiro RF Jr, Potratz FF, Pavan BM, Foreichi L, Lima FL, Fiorni J, et al. Cardiovillid prevents ovariectomy-induced myocardial contractile dysfunction in female rat. PLoS One. 2013;8:e53226.

12. Sun J, Zhou W, Gu T, Zhu D, Bi Y. A retrospective study on association between obesity and cardiovascular risk diseases with aging in Chinese adults. Sci Rep. 2018;8:5806.

13. Pratheyasakul W, Kerdphoo S, Petsophasakul P, Pongchaidecha A, Chattipakorn N, Chattipakorn SC. Effects of high-fat diet on insulin receptor function in rat hippocampus and the level of neuronal corticoside. Life Sci. 2011;88:1519–27.

14. Apajai N, Chinda K, Pole S, Chattipakorn S, Chattipakorn N. Combined vildaglaptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats. PLoS One. 2014;9:e103237.

15. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88:2404–11.

16. Pungkan W, Pintana H, Sivasinprasaisan S, Jawongkham T, Chattipakorn SC, Chattipakorn N. Testosterone deprivation accelerates cardiac dysfunction in obese male rats. J Endocrinol. 2016;229:209–20.

17. Pratheyasakul W, Chattipakorn N, Chattipakorn SC. Estrogen restores brain insulin sensitivity in ovariectomized non-obese rats, but not in ovariectomized obese rats. Metabolism. 2014;63:851–9.

18. Apajai N, Pintana H, Chattipakorn SC, Chattipakorn N. Cardioprotective effects of metformin and vildaglaptin in adult rats with insulin resistance induced by a high-fat diet. Endocrinology. 2012;153:3878–85.

19. Chattipakorn N, Incharoen T, Kanlop N, Chattipakorn S. Heart rate variability in myocardial infarction and heart failure. Int J Cardiol. 2007;110:289–96.

20. Glos M, Romberg D, Fieze I, Penzel T. Heart rate and systolic blood pressure variability before and during obstructive sleep apnea episodes. Conf Proc IEEE Eng Med Biol Soc. 2007;2007:263–6.

21. Latchman PL, Mathur M, Burtick MN, Antell RS, De, Meersman RE. Improved autonomic function in normotensive obese children. Clin Auton Res. 2011;21:319–23.

22. Thummasorn S, Kumfu S, Chattipakorn S, Chattipakorn N. Granulocyte colony stimulating factor attenuates mitochondrial dysfunction induced by oxidative stress in cardiac mitochondria. Mitochondrion. 2011;11:457–66.

23. Chinda K, Sanit J, Chattipakorn S, Chattipakorn N. Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemia-reperfusion rat heart. Diab Vasc Dis Res. 2014;11:75–83.

24. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.

25. Appleton DJ, Rand JS, Sunvold GD. Basal plasma insulin and homeostasis model assessment (HOMA) are indicators of insulin sensitivity in cats. J Feline Med Surg. 2005;7:183–93.

26. Mateos R, Lecumberri E, Ramos S, Goya L, Bravo L. Determination of malondialdehyde (MDA) by high-performance liquid chromatography in serum and liver as a biomarker for oxidative stress. Application to a rat model for hypercholesterolemia and evaluation of the effect of diets rich in phenolic antioxidants from fruits. J Chromatogr B Anal Technol Biomed Life Sci. 2005;827:76–82.

27. Moran A, Jacobs DR Jr, Steinberger J, Hong CP, Prineas R, Luepker R, et al. Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes. 1999;48:2039–44.

28. Travers SH, Jeffers BW, Eckel RH. Insulin resistance during puberty and future fat accumulation. J Clin Endocrinol Metab. 2002;87:3814–8.

29. Williams JW, Zimmet PZ, Shaw JE, de Courten MP, Cameron AJ, Chitos P, et al. Gender differences in the prevalence of impaired fasting glycaemia and impaired glucose tolerance in Mauritius. Does sex matter? Diabet Med. 2003;20:915–20.

30. Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-Kurktschiev T, et al. Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance for Atherosclerosis and Diabetes study. Diabetes Care. 2003;26:686–74.

31. Barrett-Conner E, Ferrara A. Isolated postchallenge hyperglycaemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care. 1998;21:1236–9.

32. Regitz-Zagrosek V, Lemhmkul E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol. 2006;95:136–47.

33. Karmazyn M, Purdham DM, Rajapurohitam V, Zeidan A. Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart. Cardiovasc Res. 2008;79:79–86.

34. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79–83.

35. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595–9.

36. Sivasinprasaisan S, Sa-Nguammoon P, Pratcharaysakul W, Kumfu S, Chattipakorn SC, Chattipakorn N. Obese-insulin resistance accelerates and aggravates cardiometabolic disorders and cardiac mitochondrial dysfunction in estrogen-deprived female rats. Age (Dordr). 2015;37:28.

37. Apajai N, Pintana H, Chattipakorn SC, Chattipakorn N. Effects of vildaglaptin versus sitaglaptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats. Br J Pharm. 2013;169:1048–57.

38. Ye S, Zhong H, Yamadanela S, Campese VM. Oxidative stress mediates the stimulation of sympathetic nerve activity in the phenol renal injury model of hypertension. Hypertension. 2006;48:309–15.

39. Marchini T, Magnani N, D’Annunzio V, Tasat D, Gelpi RJ, Alvarez S, et al. Impaired mitochondrial mitochondrial function and contractile reserve following an acute exposure to environmental particulate matter. Biochim Biophys Acta. 2013;1830:2545–52.

40. Colom B, Oliver J, Roca P, Garcia-Palmer FJ. Caloric restriction and gender modulate cardiac muscle mitochondrial H2O2 production and oxidative damage. Cardiovasc Res. 2007;74:456–65.

41. Lagranha CJ, Deschamps A, Aponte A, Steenbergen C, Murphy E. Sex differences in the phosphorylation of mitochondrial proteins result in reduced production of reactive oxygen species and cardioprotection in females. Circ Res. 2010;106:1681–91.

42. Malorni W, Campesi I, Straface E, Vella S, Franzoni F. Redox features of the cell: a gender perspective. Antioxid Redox Signal. 2007;9:1779–801.

43. Ribeiro RF Jr, Ronconi KS, Morra EA, Do Val Lima PR, Porto ML, Vassallo DV, et al. Sex differences in the regulation of spatially distinct cardiac mitochondrial subpopulations. Mol Cell Biochem. 2016;419:41–51.